Cullinan starts FDA review for zipalertinib in first-line lung cancer
Cullinan has begun a US Food and Drug Administration review of zipalertinib for first-line lung cancer, according to a scanx.trade news item.
Cullinan has started a review by the US Food and Drug Administration (FDA) for zipalertinib in first-line lung cancer, according to a news item published by scanx.trade on 8 November 2026.
The source consists only of a headline and gives no further detail. It does not state the type of regulatory submission, the specific lung cancer population or mutation involved, the supporting trial data, or the expected timing of any FDA decision.
LungDaily will update this report if further information is made available by the company or the regulator.
